New combo therapy shows promise in taming prostate cancer
NCT ID NCT01517451
First seen Feb 13, 2026 · Last updated May 23, 2026 · Updated 12 times
Summary
This study tested a combination of focused radiation and short-term hormone therapy in 45 men with intermediate-risk prostate cancer. The goal was to see how well the treatment controls the disease and what side effects occur. Participants received radiation over 5 sessions along with 4 months of hormone therapy, and were followed for 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE PROSTATE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
Suburban Hospital
Bethesda, Maryland, 20814, United States
-
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.